Biologics/Psoriasis

Aims: This study evaluates the long-term durability of risankizumab treatment and its ability to maintain uninterrupted disease control in patients with moderate-to-severe psoriasis.Methods: LIMMitless, a phase 3 global, multicentre, openlabel extension study, assessed the efficacy and safety of risankizumab 150 mg over 304 weeks.Adult patients who completed one of five double-blind, placebo-controlled phase 2/3 studies were eligible.Risankizumab 150 mg was administered every 12 weeks.Durability of response was measured by the proportion of patients achieving 90%/100% improvement in Psoriasis Area and Severity Index (PASI 90/PASI 100) or a Dermatology Life Quality Index score of 0 or 1 (DLQI 0/1) at various time points.Additional efficacy assessments included high disease control and remission at multiple intervals over five years.Results are presented for all patients and those with (bio-experienced) or without (bio-nave) prior biologic therapy.Data are reported as observed cases with no imputation for missing data.Results: Of 897 enrolled, 661 (73.7%) completed the study.At baseline (week 52), PASI 90, PASI 100, and DLQI 0/1 were achieved by 86.3%, 58.3%, and 77.9% of patients, respectively.At week 304, these outcomes were maintained by 93.3%, 78.0%, and 91.4%, and similar trends were observed for bio-experienced and bio-nave patients (Table 1).For more than one to five years, high disease control was between 89.3% and 68.0% for PASI 90 and between 93.8% and 66.2% for DLQI 0/1 (Table 2).Remission rates ranged between 70.5% and 37.1%.Again, results for bioexperienced and bio-nave patients were comparable.Long-term risankizumab safety is reported elsewhere.Conclusions: Risankizumab offers durable and long-term disease control, maintaining a high level of psoriasis management and remission for up to five years in patients achieving treatment goals after 52 weeks.